Related Experiment Video

Updated: Aug 7, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K

A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine

Martin Sattler1,2, Isa Mambetsariev3, Jeremy Fricke3

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA 02215, USA.

Journal of Clinical Medicine
|March 11, 2023
PubMed

Insights

Epidermal growth factor receptor (EGFR) inhibitors offer benefits but are not curative. Understanding both genetic and nongenetic resistance mechanisms is crucial for developing effective combination therapies.

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Small-molecule inhibitors targeting the epidermal growth factor receptor (EGFR) have improved patient outcomes.
  • Current EGFR inhibitors are not curative and face challenges due to on-target mutations causing resistance.
  • Genomic studies reveal complex on-target and off-target resistance mechanisms to existing EGFR inhibitors.

Purpose of the Study:

  • To explore the multifaceted mechanisms of EGFR inhibitor resistance.
  • To highlight the significance of both genetic and nongenetic resistance pathways.
  • To discuss emerging therapeutic strategies, including combination therapies, to overcome resistance.

Main Methods:

  • Review of genomic studies identifying on-target and off-target resistance mutations.
  • Analysis of non-genetic resistance mechanisms contributing to treatment failure.
  • Examination of current clinical and drug development research for combination therapies.

Main Results:

  • EGFR inhibitor resistance is more complex than initially anticipated, involving both on-target and off-target genetic alterations.
  • Non-genetic resistance mechanisms account for a significant proportion (up to 50%) of treatment escape pathways.
  • Novel therapeutics are needed to overcome these diverse resistance mechanisms.

Conclusions:

  • A comprehensive understanding of both genetic and non-genetic resistance is essential for advancing EGFR inhibitor therapy.
  • Combination therapy approaches, integrating clinical and research efforts, hold promise for overcoming resistance.
  • Future research should focus on targeting both genetic and non-genetic resistance pathways for improved patient outcomes.
Keywords:
EGFRdrug resistanceepigeneticsgenetic/nongeneticnon-small cell lung cancer

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K